Research ExplorerPublicationsFactors associated with the dosing of edoxaban for stroke pr...

Factors associated with the dosing of edoxaban for stroke prevention in patients with atrial fibrillation from South Korea and Taiwan: 1-year data from the Global ETNA-AF Program

Standard

Factors associated with the dosing of edoxaban for stroke prevention in patients with atrial fibrillation from South Korea and Taiwan: 1-year data from the Global ETNA-AF Program. / Chao, Tze-Fan; Hong, Keun-Sik; Lee, Byung-Chul; De Caterina, Raffaele; Kirchhof, Paulus; Reimitz, Paul-Egbert; Chen, Cathy; Unverdorben, Martin; Wang, Chun-Chieh.

In: J CHIN MED ASSOC, Vol. 84, No. 5, 01.05.2021, p. 485-490.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Chao, T-F, Hong, K-S, Lee, B-C, De Caterina, R, Kirchhof, P, Reimitz, P-E, Chen, C, Unverdorben, M & Wang, C-C 2021, 'Factors associated with the dosing of edoxaban for stroke prevention in patients with atrial fibrillation from South Korea and Taiwan: 1-year data from the Global ETNA-AF Program', J CHIN MED ASSOC, vol. 84, no. 5, pp. 485-490. https://doi.org/10.1097/JCMA.0000000000000516

APA

Chao, T-F., Hong, K-S., Lee, B-C., De Caterina, R., Kirchhof, P., Reimitz, P-E., Chen, C., Unverdorben, M., & Wang, C-C. (2021). Factors associated with the dosing of edoxaban for stroke prevention in patients with atrial fibrillation from South Korea and Taiwan: 1-year data from the Global ETNA-AF Program. J CHIN MED ASSOC, 84(5), 485-490. https://doi.org/10.1097/JCMA.0000000000000516

Vancouver

Chao T-F, Hong K-S, Lee B-C, De Caterina R, Kirchhof P, Reimitz P-E et al. Factors associated with the dosing of edoxaban for stroke prevention in patients with atrial fibrillation from South Korea and Taiwan: 1-year data from the Global ETNA-AF Program. J CHIN MED ASSOC. 2021 May 1;84(5):485-490. https://doi.org/10.1097/JCMA.0000000000000516

Bibtex

@article{b21e9d00dd37440b882be5dc5aa63057,
title = "Factors associated with the dosing of edoxaban for stroke prevention in patients with atrial fibrillation from South Korea and Taiwan: 1-year data from the Global ETNA-AF Program",
abstract = "BACKGROUND: Direct oral anticoagulants (DOACs) have replaced vitamin K antagonists as the standard of care for stroke prevention in patients with atrial fibrillation (AF). However, DOAC prescriptions at dosages that do not adhere to labeling are common in daily practice. This analysis from the observational Global Edoxaban Treatment in routiNe clinical prActice (ETNA)-AF program focuses on edoxaban-treated patients from South Korea and Taiwan to identify patient baseline characteristics that may be associated with non-recommended dosing.METHODS: We report baseline data from ETNA-AF, including patient demographics, clinical characteristics, and bleeding/stroke history of patients receiving recommended or non-recommended edoxaban dosing.RESULTS: A total of 2677 patients were enrolled. Among 1543 patients who did not meet dose-reduction criteria, 1033 (66.9%) were prescribed the recommended 60-mg dose, and 510 (33.1%) were prescribed the non-recommended 30-mg dose. Among 1134 patients meeting ≥1 of the dose-reduction criteria, 863 (76.1%) were prescribed the recommended 30-mg dose; 271 (23.9%) were prescribed the nonrecommended 60-mg dose. Compared with the recommended 60-mg group, the nonrecommended 30-mg group had a higher proportion of patients aged ≥75 years, higher stroke and bleeding risks, and a history of major bleeding. The non-recommended 60-mg group had a lower proportion of patients aged ≥75 years, a higher history of stroke, and lower history of bleeding compared with the recommended 30-mg group.CONCLUSION: The baseline data from ETNA-AF indicate that physicians take patient clinical characteristics (e.g., bleeding risks) into consideration when deviating from the dosing recommendation per label.",
keywords = "Administration, Oral, Aged, Anticoagulants/administration & dosage, Atrial Fibrillation/drug therapy, Databases, Factual, Factor Xa Inhibitors/administration & dosage, Female, Humans, Male, Middle Aged, Pyridines/administration & dosage, Republic of Korea, Stroke/prevention & control, Taiwan, Thiazoles/administration & dosage",
author = "Tze-Fan Chao and Keun-Sik Hong and Byung-Chul Lee and {De Caterina}, Raffaele and Paulus Kirchhof and Paul-Egbert Reimitz and Cathy Chen and Martin Unverdorben and Chun-Chieh Wang",
note = "Copyright {\textcopyright} 2021, the Chinese Medical Association.",
year = "2021",
month = may,
day = "1",
doi = "10.1097/JCMA.0000000000000516",
language = "English",
volume = "84",
pages = "485--490",
journal = "J CHIN MED ASSOC",
issn = "1726-4901",
publisher = "Elsevier Taiwan LLC",
number = "5",

}

RIS

TY - JOUR

T1 - Factors associated with the dosing of edoxaban for stroke prevention in patients with atrial fibrillation from South Korea and Taiwan: 1-year data from the Global ETNA-AF Program

AU - Chao, Tze-Fan

AU - Hong, Keun-Sik

AU - Lee, Byung-Chul

AU - De Caterina, Raffaele

AU - Kirchhof, Paulus

AU - Reimitz, Paul-Egbert

AU - Chen, Cathy

AU - Unverdorben, Martin

AU - Wang, Chun-Chieh

N1 - Copyright © 2021, the Chinese Medical Association.

PY - 2021/5/1

Y1 - 2021/5/1

N2 - BACKGROUND: Direct oral anticoagulants (DOACs) have replaced vitamin K antagonists as the standard of care for stroke prevention in patients with atrial fibrillation (AF). However, DOAC prescriptions at dosages that do not adhere to labeling are common in daily practice. This analysis from the observational Global Edoxaban Treatment in routiNe clinical prActice (ETNA)-AF program focuses on edoxaban-treated patients from South Korea and Taiwan to identify patient baseline characteristics that may be associated with non-recommended dosing.METHODS: We report baseline data from ETNA-AF, including patient demographics, clinical characteristics, and bleeding/stroke history of patients receiving recommended or non-recommended edoxaban dosing.RESULTS: A total of 2677 patients were enrolled. Among 1543 patients who did not meet dose-reduction criteria, 1033 (66.9%) were prescribed the recommended 60-mg dose, and 510 (33.1%) were prescribed the non-recommended 30-mg dose. Among 1134 patients meeting ≥1 of the dose-reduction criteria, 863 (76.1%) were prescribed the recommended 30-mg dose; 271 (23.9%) were prescribed the nonrecommended 60-mg dose. Compared with the recommended 60-mg group, the nonrecommended 30-mg group had a higher proportion of patients aged ≥75 years, higher stroke and bleeding risks, and a history of major bleeding. The non-recommended 60-mg group had a lower proportion of patients aged ≥75 years, a higher history of stroke, and lower history of bleeding compared with the recommended 30-mg group.CONCLUSION: The baseline data from ETNA-AF indicate that physicians take patient clinical characteristics (e.g., bleeding risks) into consideration when deviating from the dosing recommendation per label.

AB - BACKGROUND: Direct oral anticoagulants (DOACs) have replaced vitamin K antagonists as the standard of care for stroke prevention in patients with atrial fibrillation (AF). However, DOAC prescriptions at dosages that do not adhere to labeling are common in daily practice. This analysis from the observational Global Edoxaban Treatment in routiNe clinical prActice (ETNA)-AF program focuses on edoxaban-treated patients from South Korea and Taiwan to identify patient baseline characteristics that may be associated with non-recommended dosing.METHODS: We report baseline data from ETNA-AF, including patient demographics, clinical characteristics, and bleeding/stroke history of patients receiving recommended or non-recommended edoxaban dosing.RESULTS: A total of 2677 patients were enrolled. Among 1543 patients who did not meet dose-reduction criteria, 1033 (66.9%) were prescribed the recommended 60-mg dose, and 510 (33.1%) were prescribed the non-recommended 30-mg dose. Among 1134 patients meeting ≥1 of the dose-reduction criteria, 863 (76.1%) were prescribed the recommended 30-mg dose; 271 (23.9%) were prescribed the nonrecommended 60-mg dose. Compared with the recommended 60-mg group, the nonrecommended 30-mg group had a higher proportion of patients aged ≥75 years, higher stroke and bleeding risks, and a history of major bleeding. The non-recommended 60-mg group had a lower proportion of patients aged ≥75 years, a higher history of stroke, and lower history of bleeding compared with the recommended 30-mg group.CONCLUSION: The baseline data from ETNA-AF indicate that physicians take patient clinical characteristics (e.g., bleeding risks) into consideration when deviating from the dosing recommendation per label.

KW - Administration, Oral

KW - Aged

KW - Anticoagulants/administration & dosage

KW - Atrial Fibrillation/drug therapy

KW - Databases, Factual

KW - Factor Xa Inhibitors/administration & dosage

KW - Female

KW - Humans

KW - Male

KW - Middle Aged

KW - Pyridines/administration & dosage

KW - Republic of Korea

KW - Stroke/prevention & control

KW - Taiwan

KW - Thiazoles/administration & dosage

U2 - 10.1097/JCMA.0000000000000516

DO - 10.1097/JCMA.0000000000000516

M3 - SCORING: Journal article

C2 - 33742992

VL - 84

SP - 485

EP - 490

JO - J CHIN MED ASSOC

JF - J CHIN MED ASSOC

SN - 1726-4901

IS - 5

ER -